The U.S. FDA has officially approved the first new drug for Alzheimer’s diseases. The drug called ‘Aduhelm’, manufactured by Biogen is intended to slow cognitive brain decline in patients with mild cognitive impairment. Despite its promises, the drug is set at a whopping price tag of $56,000. However, executives at Biogen say they expect the drug to be mostly covered by Medicare for most of its patients. It is estimated that over 6.2 million Americans suffer from the debilitating disease. Health care reporter at POLITICO Sarah Owermohle and Senior Vice President and System Chair of the Neuroscience Institute Dr. Paul Wright, joined Cheddar to discuss the potential historic medical breakthrough for Alzheimer’s disease and what patients should expect if they are interested in starting the treatment.